Exalenz Bioscience Ltd

EXEN

IL0011048688

Medical Equipment, Supplies & Distribution

Delayed TEL AVIV STOCK EXCHANGE Other stock markets			5-day change	1st Jan Change
- ^ILa	-.--%		+1.39%	+107.88%

2020	Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others.	CI
2020	Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million.	CI

Exalenz Bioscience Ltd Appoints Larry Cohen as CEO

March 04, 2013 at 01:30 pm

Exalenz Bioscience Ltd. has reported the appointment of Larry Cohen as the company's CEO. His recent positions, he was the CEO of the HEMOSENSE and President of International Technidyne Corp.

Latest news about Exalenz Bioscience Ltd

Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others.	29/04/20	CI
Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million.	18/02/20	CI
Exalenz Bioscience Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019	14/08/19	CI
Exalenz Bioscience Receives Approval for Commercial Marketing in China for Its Breathid® HP Lab System	25/02/19	CI
Exalenz Bioscience Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	15/11/18	CI
Exalenz Bioscience Ltd Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2018	31/08/18	CI
Exalenz Bioscience Ltd. Announces BreathID®13C-methacetin Breath Test	10/07/18	CI
Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer	30/04/18	CI
Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients	13/03/18	CI
Exalenz Bioscience Ltd Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017; Provides Earnings Guidance for the Year 2018 and Revenue Guidance for the Year 2019	12/03/18	CI
Exalenz Bioscience Announces Positive Clinical Trial Results for the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients	24/01/18	CI
Exalenz Bioscience Ltd Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori Detection	17/08/17	CI
Exalenz Bioscience Plans For Nasdaq IPO	14/08/17	CI
Exalenz Bioscience Receives FDA Marketing Clearance for its Laboratory System in the United States	01/11/16	CI
Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to Use BreathID to Monitor Patients with Cirrhosis Associated with NASH	03/08/15	CI
Exalenz Bioscience Ltd and Galectin Therapeutics, Inc. Receive FDA Approval for Joint Clinical Trial of Second-Stage of GR-MD-02	02/08/15	CI
Exalenz Bioscience Ltd Launches Clinical Study for Breath-Based Detection of Primary Liver Cancer	04/06/15	CI
Exalenz Bioscience Launches Additional Clinical Study of Breath-Based Diagnostic Test	06/05/15	CI
Exalenz Bioscience Ltd. Auditor Raises 'Going Concern' Doubt	25/02/15	CI
Exalenz Bioscience Launches Pivotal Study of Breath-Based Test to Diagnose Clinically Significant Portal Hypertension	21/10/14	CI
Exalenz Bioscience Expands its Breath Testing Technology into the Potential Billion Dollar Liver Diagnostic Market	21/05/14	CI
Exalenz Bioscience Appoints Gavin Doree as New Vice President of Sales	23/07/13	CI
Exalenz Bioscience Ltd Announces the Global Market Launch of the New BreathID(R) Hp for Detection and Management of H. pylori	15/07/13	CI
Exalenz Bioscience Ltd Names Ted Foltyn as New VP of Worldwide Marketing and Business Development	24/06/13	CI
Exalenz Bioscience Ltd Announces Consolidated Earnings Results for the Year Ended December 31, 2012	18/03/13	CI

Exalenz Bioscience Ltd is an Israel-based company active in the medical sector. It develops and commercializes advanced systems that extract vital information for diagnostics from subtle changes in the patient's exhaled breath. Its core technology enables medical specialists to identify and manage specific digestive and liver conditions. The Company's product, the BreathID System, is used for assessment and monitoring of functional diseases of the liver and gastrointestinal tract. The BreathID System is mobile and can be operated in any clinical setting. The Company conducts ongoing research in collaboration with clinical and industrial partners in the United States, Europe, Asia, and Israel.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
EXALENZ BIOSCIENCE LTD	+107.88%	45.97M
ABBOTT LABORATORIES	-7.16%	178B
MEDTRONIC PLC	-1.23%	107B
BECTON, DICKINSON AND COMPANY	-4.86%	67.04B
DEXCOM, INC.	-4.28%	47.23B
CENCORA, INC.	+10.32%	44.62B
HOYA CORPORATION	+9.25%	42.5B
TERUMO CORPORATION	+15.97%	25.22B
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	24.14B
ZIMMER BIOMET HOLDINGS, INC.	-5.38%	23.69B

Other Medical Equipment, Supplies & Distribution